Gradient performance in tumor characterization at Vanderbilt University Institute of Imaging Science

By Philips ∙ Featuring Prof. Junzhong Xu | March, 2024 | 2:47 min

Radiology

Magnetic resonance

Video

Diagnostic confidence

MR 7700

Neuro

Gradient performance tumor characterization at Vanderbilt University Institute of Imaging Science

At a glance

 
  • Hear how Vanderbilt is able to detect change in tumor morphology to provide a much earlier response
  • See how a technology is used that provides cell size, cell density and membrane permeability information to know the exact response of cancer cells to distinguish recurring brain tumors from radiation induced injuries

Dr. Junzhong Xu, Director of Cancer Imaging Research at the Vanderbilt University Institute of Imaging Science discusses the development of MR cell size imaging [1] utilizing diffusion MRI. The imaging technique provides real-time data on cell size, density and membrane permeability and gradient strength is crucial for accurate measurements. The technology's ability to differentiate recurrent brain tumors from radiation injuries and track cell changes associated with chemotherapy-induced apoptosis is groundbreaking.

“Our ability to detect accurate mean cell size in tumors relies on the gradient strength we have. The stronger gradients we have, the more accurate and reliable measurements we can make. We will develop and validate a more advanced technology to evaluate tumors more comprehensively.”

Junzhong Xu, PhD
Director of Cancer Imaging Research
Vanderbilt University Institute of Imaging Science

Register for the Radiology Insights newsletter


Our periodic Radiology Insights newsletter provides you with the latest articles on user experiences and best practices.

我們一直有興趣與您互動

告訴我們該怎麼幫助你

1
選擇您感興趣的領域
2
聯繫方式

Footnotes
 

[1] MR cell size imaging is being developed by the VUIIS and is not a product.

You are about to visit a Philips global content page

Continue

You are about to visit a Philips global content page

Continue

使用最新版 Microsoft Edge、Google Chrome 或 Firefox 瀏覽本網站效果最佳。